钠-葡萄糖共转运蛋白2抑制剂在非酒精性脂肪性肝病中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.10.1594

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (10): 1594-1598.doi: 10.16352/j.issn.1001-6325.2023.10.1594

钠-葡萄糖共转运蛋白2抑制剂在非酒精性脂肪性肝病中作用的研究进展

黄李晨露¹, 张家瑞¹, 郑永钦², 贺军栋^2*

1.昆明理工大学医学院,云南昆明 650500;
2.昆明理工大学附属医院云南省第一人民医院内分泌代谢科,云南昆明 650500

收稿日期:2022-12-12 修回日期:2023-04-10 出版日期:2023-10-05 发布日期:2023-10-05
通讯作者: *hejd1227@163.com
基金资助:
云南省中青年学术和技术带头人后备人才(2018HB050);云南省万人计划青年拔尖人才(YNWR-QNBJ-2018-070);云南省临床医学中心开放课题(2021LCZXXF-NM04)

Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease

HUANG Lichenlu¹, ZHANG Jiarui¹, ZHENG Yongqin², HE Jundong^2*

1. Medical School,Kunming University of Science and Technology,Kunming 650500;
2. Department of Endocrinology and Metabolism, the Affiliated Hospital of Kunming University of Science and Technology, the First People's Hospital of Yunnan Province,Kunming 650500, China

Received:2022-12-12 Revised:2023-04-10 Online:2023-10-05 Published:2023-10-05
Contact: *hejd1227@163.com

摘要/Abstract

摘要： 钠-葡萄糖共转运蛋白2抑制剂(SGLT-2i)是一种新型的抗糖尿病药物,临床研究发现SGLT-2i在非酒精性脂肪性肝病(NAFLD)患者的治疗中发挥有益作用。SGLT-2i可以降低肝细胞内质网应激,调节炎性反应,改善肝脏纤维化,上调肝细胞自噬以减轻NAFLD患者的症状。

关键词: 非酒精性脂肪性肝病, 钠-葡萄糖共转运蛋白2抑制剂

Abstract: Sodium-glucose cotransporter 2 inhibitor (SGLT-2i) is a new type of anti-diabetes drug. Clinical studies have shown that SGLT-2i plays a beneficial role in the treatment of patients with non-alcoholic fatty liver disease (NAFLD). SGLT-2i can reduce hepatic endoplasmic reticulum stress, regulate inflammatory reaction, improve liver fibrosis and increase hepatocyte autophagy to alleviate symptoms of NAFLD patients.

Key words: non-alcoholic fatty liver disease, sodium-glucose cotransporter 2 inhibitor

中图分类号:

R392

黄李晨露, 张家瑞, 郑永钦, 贺军栋. 钠-葡萄糖共转运蛋白2抑制剂在非酒精性脂肪性肝病中作用的研究进展[J]. 基础医学与临床, 2023, 43(10): 1594-1598.

HUANG Lichenlu, ZHANG Jiarui, ZHENG Yongqin, HE Jundong. Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease[J]. Basic & Clinical Medicine, 2023, 43(10): 1594-1598.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.10.1594

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I10/1594

参考文献

[1]史冬雪,原佳琪,丁宝锋等. 非酒精性脂肪肝病模型小鼠的肝脏病理变化及肝细胞获取方法[J]. 基础医学与临床, 2022, 42:890-895
[2]Donne R,Saroul-Ainama M,Cordier P,et al. Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD[J]. Dev Cell, 2022, 57:1728-1741.e6.
[3]Aragón-Herrera A,Otero-Santiago M,Anido-Varela L,et al. The treatment with the SGLT2 inhibitor empagliflozin modifies the hepatic metabolome of male zucker diabetic fatty rats towards a protective profile[J]. Front Pharmacol, 2022, 13:827033.doi:827010.823389/fphar.822022.827033.
[4]Wang S,Sheng F,Zou L,et al. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism[J]. J Adv Res, 2021, 34:109-122.
[5]Li L,Li Q,Huang W,et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway[J]. Front Pharmacol,2021, 12:589273.doi:589210.583389/fphar.582021.589273.
[6]Latif M,Schmidt G,Mercan S,et al. NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression[J]. Gut, 2022, 71:2561-2573.
[7]Murakami K,Sasaki Y,Asahiyama M,et al. Selective PPARα modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor Tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis[J]. Cells, 2022, 11:720.doi:710.3390/cells11040720.
[8]Nasiri-Ansari N,Nikolopoulou C,Papoutsi K,et al. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(-/-) mice by activating autophagy and reducing ER stress and apoptosis[J]. Int J Mol Sci, 2021, 22:818.doi:810.3390/ijms22020818.
[9]Zhu W,Sahar N,Javaid H,et al. Exercise-induced irisin decreases inflammation and improves NAFLD by competitive binding with MD2[J]. Cells, 2021, 10:3306.doi:3310.3390/cells10123306.
[10]Xu Z,Hu W,Wang B,et al. Canagliflozin ameliorates nonalcoholic fatty liver disease by regulating lipid metabolism and inhibiting inflammation through induction of autophagy[J]. Yonsei Med J, 2022, 63:619-631.
[11]Ozutsumi T,Namisaki T,Shimozato N,et al. Combined treatment with sodium-glucose cotransporter-2 inhibitor (Canagliflozin) and dipeptidyl peptidase-4 inhibitor (Teneligliptin) alleviates NASH progression in a non-diabetic rat model of steatohepatitis[J]. Int J Mol Sci, 2020, 21:2164.doi:2110.3390/ijms21062164.
[12]Morishita A,Tadokoro T,Fujihara S,et al. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model[J]. PLoS One, 2022, 17:e0261310.doi:0261310.0261371/journal.pone.0261310.
[13]Elmahdy MK,Helal MG,Ebrahim TM. Potential anti-inflammatory effect of dapagliflozin in HCHF diet-induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver[J]. Int Immunopharmacol, 2020, 86:106730.doi: 10.1016/j.intimp.2020.106730.
[14]Hüttl M,Markova I,Miklankova D,et al. In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia[J]. Int J Mol Sci, 2021, 22:11513.doi:11510.13390/ijms222111513.
[15]Perakakis N,Chrysafi P,Feigh M,et al. Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH[J]. Int J Mol Sci, 2021, 22:6332.doi:6310.3390/ijms22126332.
[16]Meng Z,Liu X,Li T,et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway[J]. Int Immunopharmacol, 2021, 94:107492.
[17]Hupa-Breier K,Dywicki J,Hartleben B,et al. Dulaglutide alone and in combination with empagliflozin attenuate inflammatory pathways and microbiome dysbiosis in a non-diabetic mouse model of NASH[J]. Biomedicines, 2021, 9:353.doi:310.3390/biomedicines9040353.
[18]Cai B,Dongiovanni P,Corey K,et al. Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis[J]. Cell Metab, 2020, 31:406-421.e407.
[19]Yoshioka N,Tanaka M,Ochi K,et al. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model[J]. Biomed Pharmacother, 2021, 140:111738.doi: 10.1016/j.biopha.2021.111738.
[20]Kimura A,Kamimura K,Ohkoshi-Yamada M,et al. Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model[J]. Biochem Biophys Res Commun,2022, 596:76-82.
[21]Jojima T,Wakamatsu S,Kase M,et al. The SGLT2 inhibitor Canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma[J]. Int J Mol Sci, 2019, 20:5237.doi:5210.3390/ijms20205237.

钠-葡萄糖共转运蛋白2抑制剂在非酒精性脂肪性肝病中作用的研究进展

Research progress of sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	王鑫瑞, 秦燕. Ghrelin在代谢性疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1299-1303.
[2]	郝丹丹, 张垒, 白春英. 靶向铁死亡治疗非酒精性脂肪性肝病的研究进展[J]. 基础医学与临床, 2023, 43(8): 1317-1321.
[3]	胡诗琪, 蓝彦琦, 吴寿岭, 王晓墨, 陈朔华, 汪国栋, 王丽. 肥胖及其变化对中国华北新发NAFLD成年男性患者心血管疾病发病风险的影响[J]. 基础医学与临床, 2022, 42(5): 788-794.
[4]	许可, 胡珦, 虞伟慧, 杨丽娟, 顾雪疆. 代谢健康型肥胖与非酒精性脂肪性肝病患病率的相关性[J]. 基础医学与临床, 2021, 41(6): 837-841.